Author  
Place of duty  
Title   진행대장암환자에 대한 5 - Fluorouracil 및 재조합 감마 인터페론 병용요법의 치료효과 ( Phase 2 study of 5 - Fluorouracil amd Recombinant Interferon - gamma in Patients with Advanced Colorectal Cancer )
Publicationinfo   1992 Jan; 024(05): 743-759.
Key_word   5-F1uorouracil, Recombinant interferon-gamma, Advanced colorectal cancer
Full-Text  
Abstract   We observed synergism between 5-f1uorouracil(5-FU) and recombinant interferon-gamma (IFN-r) against 2 human colon cancer cell lines. Based on this in vitro study, we conducted a phase II trial of 5-FU and IFN-r in 45 patients with advanced colorectal cancer with measurable lesions between June 1990 and October 1991. 5-FU was administered as a loading schedule, 12 mg/kg/day daily for 4 days by intravenous bolus followed by 4 half doses on alternate days. Ten days after completion of the loading course the weekly doses of 15 mg/kg/day(not to exceed 1 g) were given. IFN-r, 2 x 10 IU/M, was administered intramuscularly three times per week. Patients were categorized into 3 groups as previously untreated group, recurrent and refractory group. Recurrent group consisted of 6 patients who had relapsed after the completion of adjuvant chemotherapy and refractory group consisted of 18 patients who had failed while receiving adjuvant or palliative chemotherapy. Among 41 evaluable patients the response rate were 35%, 50%, 6% for previously untreated, recurrent and refractory group, respectively.(P<0.005) With a median follow-up of 30weeks, median survivals of previously untreated group and refractory group were 42 weeks and 43 weeks. In recurrent group, median survival had not been reached, with a median follow-up of 30 weeks.(P<0.005) NK activity and immunophenotyPing of peripheral blood lymphocytes following this combi- nation therapy were not changed significantly. Clinical response was not correleated to changes in NK activity. Common toxicities were flu-like symptoms(35%), leukopenia(28%), stomatitis(18%) and diarrhea(7%). But only 1% of patients developed grade 3 toxicity. We conclude that the combination of 5-FU and IFN-r is an active and safe regimen against advanced colorectalcancerin previously untreated or relapsed patients.
저 자   김흥태(Heung Tae Kim),서창인(Chang In Suh),김시영(Si Young Kim),허대석(Dae Seog Heo),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim)